{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045016189824.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1080/019262301753178465"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/pdf/10.1080/019262301753178465"}},{"identifier":{"@type":"NAID","@value":"30016887733"}}],"dc:title":[{"@value":"p53 +/- Hemizygous Knockout Mouse: Overview of Available Data"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p> The performance of the p53 +/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21 compounds tested as part of the International Life Sciences Institute's (ILSI) Alternatives to Carcinogenicity Testing (ACT) project, together with data from other studies which used comparable protocols. As expected based on the hypothesis for the model, a significant number (12/16 or 75%) of the genotoxic human and/or rodent carcinogens tested were positive and the positive control, p-cresidine, gave reproducible responses across laboratories (18/19 studies positive in bladder). An immunosuppressive human carcinogen, cyclosporin A, was positive for lymphomas but produced a similar response in wild type mice. Two hormones that are human tumorigens, diethylstilbestrol and 17β-estradiol, gave positive and equivocal results, respectively, in the pituitary with p53-defi cient mice showing a greater incidence of proliferative lesions than wild type. None of the 22 nongenotoxic rodent carcinogens that have been tested produced a positive response but 2 compounds in this category, chloroform and diethylhexylphthalate, were judged equivocal based on effects in liver and kidney respectively. Four genotoxic noncarcinogens and 6 nongenotoxic, noncarcinogens were also negative. In total (excluding compounds with equivocal results), 42 of 48 compounds or 88% gave results that were concordant with expectations. The technical lessons learned from the ILSI ACT-sponsored testing in the p53+/- model are discussed. </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045016189829","@type":"Researcher","foaf:name":[{"@value":"Richard D. Storer"}],"jpcoar:affiliationName":[{"@value":"Merck & Co Inc, West Point, Pennsylvania 19486, richardstorer@merck.com"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189831","@type":"Researcher","foaf:name":[{"@value":"John E. French"}],"jpcoar:affiliationName":[{"@value":"National Institute of Environmental Health Sciences,\rResearch Triangle Park, North Carolina 27709"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189830","@type":"Researcher","foaf:name":[{"@value":"Joseph Haseman"}],"jpcoar:affiliationName":[{"@value":"National Institute of Environmental Health Sciences,\rResearch Triangle Park, North Carolina 27709"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189824","@type":"Researcher","foaf:name":[{"@value":"Gerald Hajian"}],"jpcoar:affiliationName":[{"@value":"Schering Plough Research Institute, Kenilworth, New\rJersey 07083"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189832","@type":"Researcher","foaf:name":[{"@value":"Edmund K. Legrand"}],"jpcoar:affiliationName":[{"@value":"RW Johnson Pharmaceutical Research Institute, Raritan\rNew Jersey 08869"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189696","@type":"Researcher","foaf:name":[{"@value":"Gerald G. Long"}],"jpcoar:affiliationName":[{"@value":"Eli Lilly & Co, Greenfield, Indiana 46140"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189826","@type":"Researcher","foaf:name":[{"@value":"Lori A. Mixson"}],"jpcoar:affiliationName":[{"@value":"Merck & Co Inc, West Point, Pennsylvania 19486"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189825","@type":"Researcher","foaf:name":[{"@value":"Ricardo Ochoa"}],"jpcoar:affiliationName":[{"@value":"Pfizer, Inc, Groton, Connecticut 06340"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189828","@type":"Researcher","foaf:name":[{"@value":"John E. Sagartz"}],"jpcoar:affiliationName":[{"@value":"Monsanto, St. Louis, MO 63141"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045016189827","@type":"Researcher","foaf:name":[{"@value":"Keith A. Soper"}],"jpcoar:affiliationName":[{"@value":"Merck & Co Inc, West Point, Pennsylvania 19486"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01926233"},{"@type":"EISSN","@value":"15331601"}],"prism:publicationName":[{"@value":"Toxicologic Pathology"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2001-01","prism:volume":"29","prism:number":"1_suppl","prism:startingPage":"30","prism:endingPage":"50"},"reviewed":"false","dc:rights":["https://journals.sagepub.com/page/policies/text-and-data-mining-license"],"url":[{"@id":"https://journals.sagepub.com/doi/pdf/10.1080/019262301753178465"}],"createdAt":"2003-01-30","modifiedAt":"2025-03-10","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050001202563313152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"LIVE IMAGING BY TIME-LAPSE MICROSCOPY CAN MORE CLEARLY EVALUATE THE ANTI-APOPTOTIC STATE OF PRIMARY HEPATOCYTES ISOLATED FROM THE DRS KNOCKOUT MOUSE"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204414417024","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Current Status of Carcinogenicity Assessment of Peroxisome Proliferator-Activated Receptor Agonists by the US FDA and a Mode-of-Action Approach to the Carcinogenic Potential"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204414957568","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lack of Enhanced Epithelial Cell Proliferation in the Urinary Bladder of Heterozygous p53 Knockout Mice Given Sodium <i>Ortho</i>-phenylphenate or Uracil"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204901114880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"POSSIBLE MECHANISM ON ENHANCED CARCINOGENESIS OF GENOTOXIC CARCINOGENS AND UNSOLVED MECHANISMS ON LESSER CARCINOGENIC SUSCEPTIBILITY TO SOME CARCINOGENS IN RASH2 MICE."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204903400448","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Gene expression analysis in the lung of the rasH2 transgenic mouse at week 4 prior to induction of malignant tumor formation by urethane and N-methylolacrylamide"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679391653376","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Susceptibility of Heterozygous and Nullizygous p53 Knockout Mice to Chemical Carcinogens: Tissue Dependence and Role of p53 Gene Mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/2051714791867900032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Transgenic rat models for mutagenesis and carcinogenesis"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1080/019262301753178465"},{"@type":"CIA","@value":"30016887733"},{"@type":"CROSSREF","@value":"10.1186/s41021-016-0072-6_references_DOI_GafWaBMjblwyiwgsuB3ioyLb4Bu"},{"@type":"CROSSREF","@value":"10.1293/tox.18.121_references_DOI_GafWaBMjblwyiwgsuB3ioyLb4Bu"},{"@type":"CROSSREF","@value":"10.1293/tox.20.197_references_DOI_GafWaBMjblwyiwgsuB3ioyLb4Bu"},{"@type":"CROSSREF","@value":"10.2131/jts.28.371_references_DOI_GafWaBMjblwyiwgsuB3ioyLb4Bu"},{"@type":"CROSSREF","@value":"10.1293/tox.16.147_references_DOI_GafWaBMjblwyiwgsuB3ioyLb4Bu"},{"@type":"CROSSREF","@value":"10.2131/jts.40.685_references_DOI_GafWaBMjblwyiwgsuB3ioyLb4Bu"}]}